- Incannex Healthcare (IHL) selects Procaps to develop and manufacture its soft-gel capsules ahead of clinical trials
- Procaps will provide an end-to-end service that includes formulation development, clinical trial supply and manufacturing
- Meanwhile, Incannex says it’s well-advanced in its planning for phase 1 clinical trials to assess the soft gel capsules in 36 healthy volunteers
- Incannex Healthcare last traded at 27 cents on July 15
Incannex Healthcare (IHL) has selected Procaps to develop and manufacture its soft-gel capsules ahead of clinical trials.
Formulation IHL-675A is an anti-inflammatory, multi-use soft-gel capsule made up of hydroxychloroquine (HCQ) and CBD, with Procaps’ proprietary patented Unigel technology. Incannex’s development program has been assessing the potential of the treatment for lung inflammation, rheumatoid arthritis and inflammatory bowel disease.
Procaps will provide an end-to-end service that includes formulation development, clinical trial supply and manufacturing.
The company comes with a history of scientific expertise, having developed over 500 formulations for both pharmaceutical and nutritional products reaching over 50 markets globally, and are ranked within the top three companies globally for soft gel manufacturing capacity.
CEO and Managing Director of Incannex Healthcare, Joel Latham, says Procaps offers Incannex a complete supply chain solution.
“Manufacturing at Procaps will support our clinical trial programs and can also quickly ramp up production for commercial supply upon successful clinical trial outcomes,” Joel Latham said.
Meanwhile, Incannex says it’s well-advanced in its planning for phase 1 clinical trials to assess the soft gel capsules in healthy volunteers.
The study aims to demonstrate there are minimal additional side effects associated with the combination of CBD and HCQ compared to each drug alone. The trial will involve 36 participants, with each receiving either IHL-675A, CBD, or HCQ.
Incannex Healthcare last traded at 27 cents on July 15.